Efficacy and Safety Results from Comparison of Alemtuzumab and Rebif(R) Efficacy in Multiple Sclerosis II (CARE-MS II): A Phase 3 Study in Relapsing-Remitting Multiple Sclerosis Patients Who Relapsed on Prior Therapy (S01.004)

Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study

Multiple Sclerosis and Related Disorders ◽

10.1016/j.msard.2014.09.194 ◽

2014 ◽

Vol 3 (6) ◽

pp. 756 ◽

Cited By ~ 1

Author(s):

B.C. Kieseier ◽

M.A. Sahraian ◽

A.J. Coles ◽

H.P. Hartung ◽

E. Havrdova ◽

...

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Prior Therapy ◽

Relapsing Remitting ◽

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

Yearbook of Neurology and Neurosurgery ◽

10.1016/s0513-5117(09)79049-0 ◽

2009 ◽

Vol 2009 ◽

pp. 99-103

Author(s):

O. Kantarci

Keyword(s):

Multiple Sclerosis ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Relapsing Remitting ◽

Changing Disease Modifying Therapy Switching Dynamics for Relapsing-Remitting Multiple Sclerosis Patients

10.26226/morressier.59a3eda8d462b8028d895126 ◽

2017 ◽

Author(s):

Craig Wakeford

Keyword(s):

Multiple Sclerosis ◽

Disease Modifying Therapy ◽

Switching Dynamics ◽

Relapsing Remitting ◽

Disease Modifying ◽

The incidence of cognitive impairment among Hungarian relapsing-remitting multiple sclerosis patients

10.26226/morressier.59a3e8b4d462b8028d894334 ◽

2017 ◽

Author(s):

Dániel Sandi

Keyword(s):

Multiple Sclerosis ◽

Cognitive Impairment ◽

Relapsing Remitting ◽

Increased adherence and better satisfaction outcomes with oral treatments in Relapsing-Remitting Multiple Sclerosis patients

10.26226/morressier.59a3edacd462b8028d8959c3 ◽

2017 ◽

Author(s):

Ines González-Suárez

Keyword(s):

Multiple Sclerosis ◽

Relapsing Remitting ◽

Patient Reported Adherence and Treatment Satisfaction in Irish Relapsing Remitting Multiple Sclerosis Patients treated with Fingolimod

10.26226/morressier.59a3e8b7d462b8028d89583a ◽

2017 ◽

Author(s):

Niamh Murphy

Keyword(s):

Multiple Sclerosis ◽

Treatment Satisfaction ◽

Patient Reported ◽

Relapsing Remitting ◽

EVOLVE-MS-1: a phase 3, open-label, long-term safety study of ALKS 8700 in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8952fe ◽

2017 ◽

Author(s):

Robert T. Naismith

Keyword(s):

Multiple Sclerosis ◽

Open Label ◽

Safety Study ◽

Phase 3 ◽

Relapsing Remitting ◽

Efficacy and safety of 2 doses of ponesimod (10 and 20 mg o.d.): Interim analysis of a phase II extension trial in relapsing-remitting multiple sclerosis

10.26226/morressier.59a3edabd462b8028d8951c5 ◽

2017 ◽

Author(s):

Eva Havrdova

Keyword(s):

Multiple Sclerosis ◽

Phase Ii ◽

Interim Analysis ◽

Efficacy And Safety ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Extension Trial

Effectiveness and Safety of Long-Term Fingolimod Treatment in Relapsing-Remitting Multiple Sclerosis Patients with Highly Active Disease

10.26226/morressier.59a3e8b6d462b8028d8953f4 ◽

2017 ◽

Author(s):

Galina Vorobeychik

Keyword(s):

Multiple Sclerosis ◽

Highly Active ◽

Relapsing Remitting ◽

Relapsing Remitting Multiple Sclerosis ◽

Active Disease

Effectiveness of walking exercise program in improving fatigue in relapsing remitting multiple sclerosis patients

10.26226/morressier.5b7578655aff7400151f31e8 ◽

2018 ◽

Author(s):

Nevin M. Shalaby ◽

Alaa ElMazny

Keyword(s):

Multiple Sclerosis ◽

Exercise Program ◽

Relapsing Remitting ◽

Walking Exercise ◽